

# Welcome! We will get started shortly.

Each month's webinar slide deck & recording will be posted to <u>Healthcare Provider Home</u> Brand New Day HMO (bndhmo.com) for on demand access!









## Medicare Annual Wellness Exam (AWE) Incentive Program

Presented by Bright HealthCare



### **Our commitment to value-based care:**

Bright HealthCare's approach to risk adjustment is **member-centered**. The organization has invested significantly in different technology to help empower providers & staff with **critical member information at the point-of-care**.

This includes offering the Cozeva platform at no cost to our partners. The analytics that this technology provides and our discussions around it are intended to **improve accurate & complete capture of each member's health profile.** 

We are committed to ensuring that **all chronic conditions are assessed**, **and all treatment plans are refreshed** on at least an annual basis. This full-circle approach ensures **appropriate resource allocation for each individual member**.

# **Today's Agenda**

















#### MEDICARE PLAN

### Medicare Annual Wellness Exam (AWE) Incentive Program

Presented by Bright HealthCare



# **Program Overview**

with Janet Fina

### **2023 Medicare AWE Incentive Program**

### Janet Fina – RA Operations



To encourage member & provider engagement and improve health quality of health outcomes for our members. This program covers Bright HealthCare's Brand New Day (BND) & Central Health Plan (CHP) Medicare Advantage plans for 2023.

Scope

2.

Eligibility

There are no contract amendments needed. Some groups are excluded for different factors. If you have eligibility questions, contact your PSR.





# **Program Participation**

with Janet Fina & Elise Depew

### **Form Submissions**

Janet Fina – RA Operations

AWV forms can be accessed by providers in two ways:



1. Cozeva Electronic Form (Opt-In)

Through Cozeva, providers can access an electronic AWV form allowing on-line and real-time access to updated member specific forms.



			1	Applied Research Works, Inc.
	ill Type – Prima Ial Vielt	ry Provider	Service Date *	
eason for Visit				
Chief Complaint*	HPP			
Annual Wellness Visit				
take				
Vitals				
Temp BP*		Weight * He Ib Patient refuse measurement	ight * BMI inch s BMI	kgime
HR RR O	ximetry %	Date & Time 03/17/2023 12:54	Oxygen Source No oxygen source specified	Flow rate No flow rate specified
eton/				
istory Immunizations" influenza, high-dose, quadrivatent	Completion Complete	Status* Amou	nt	Administration Date* 08/17/2022
Immunizations*	Complete	Status* Amou	nt	
Immunizations" influenza, high-dose, quadrivalent COVID-19, mRNA, LNP-S, PF, 30 mpp/0.3 mL dose, tris-	Complete	Status' Amou	nt	08/17/2022
Immunizations" influenza, high-dose, quadrivalent COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris- surces COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose	Complete Complete	Status' Amou	nt -	08/17/2022 08/17/2022
Immunizations" Influenza, high-dose, quadrivalent OVUC-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris- surrate OOVUC-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose Influenza, injectable, quadrivalent	Complete Complete Complete Complete	Status* Amou	nt	08/17/2022 08/17/2022 11/30/2021
Immunizations" influenza, high-dose, quadrivalent COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris- surces COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose	Complete Complete Complete Complete Value	Status* Amou	nt	08/17/2022 08/17/2022 11/30/2021 10/29/2019
Immunizations" Immunizations Immunizations, S. PF, 30 mcg/0.3 mL dose, tris- succese COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose, tris- succese COVID-19, mRNA, LNP-S, PF, 30 mcg/0.3 mL dose Influenza, injectable, quadrivalent Labs* (373 11), Infectious agent artigen detection by immunizate exercise consultina (2487-604-6)	Complete Complete Complete Complete Complete Value say	Statue* Amou	n	08/17/2022 08/17/2022 11/30/2021 10/29/2019 Date
Immunizations" Immunizations I	Complete Complete Camplete Camplete Value say	Status* Amou	nt	0817/2022 0817/2022 11/30/2021 10/29/2019 Date 12/21/2022 04:20/2022
Immunizations" Immunizations I	Compilete Compilete Compilete Compilete Compilete Value say value say neret c. GC, c. C. DM) C.	Status" Amou	n	0817/2022 0917/2022 11:00:2021 10:29:2019 Date 12:21:2022 06:30:2022
Immunizations" Immunizations I	Compilete Compilete Compilete Compilete Compilete Value value etrit GCC, LC- DM/ 1 4/477 74]	Status* Amou	n	0817/2022 0817/2022 11/30/2021 10/29/2019 Date 12/21/2022 04:20/2022
Immunizations" Immunizations I	Compilete Compilete Compilete Compilete Compilete Value value etrit GCC, LC- DM/ 1 4/477 74]	Status" Amou	nt	0817/2022 0817/2022 11/30/2021 10/23/2019 Date 12/21/2022 08/30/2022 04/27/2022 04/27/2022

### **Reason for Visit**

### Intake/Vitals

### History

- Immunizations
- Labs
- Procedures
- Medications

82670). Estradiol; total				04/27/2022	
82728), Ferritin				04/27/2022	
82746), Folic acid; serum				04/27/2022	
83036), Hemoglobin; glycosylated (A1C)				04/27/2022	
83525), Insulin; total				04/27/2022	
83540), Iran				04/27/2022	
83735), Magnesium				04/27/2022	
84100). Phosphorus inorganic (phosphate)				04/27/2022	
(84144), Progesterone				04/27/2022	
(84439), Thyroxine; free				04/27/2022	
(84443), Thyroid stimulating hormone (TSH)				04/27/2022	
(84466), Transferrin				04/27/2022	
(84481), Triiodothyrenine T3; free				04/27/2022	
(85025), Blood count; complete (CBC), automated (Hgb, Hct,				04/27/2022	
RBC, WBC and platelet count) and automated differential WE count	BC				
(86140), C-reactive protein				04/27/2022	
(86769), Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID- 19])				04/27/2022	
Procedures*	Start Date		Performer	Notes	
(36415), Collection of venous blood by venipuncture	04/27/2022				
(38473), Endovenous ablation therapy of incompetent vein, axtemity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; first vein treated	09/20/2021				
(67500). Retrobulbar injection; medication (separate procedure, does not include supply of medication)	03/05/2020				
(67505), Retrobulbar injection; alcohol	03/02/2020				
Drug Description*	Quantity	Duration	Dosage Instruction	Status	All Active
shołecalciferol (vitamin D3) 125 mcg (5,000 unit) capsule		90		Unknown	
Lantus Solostar U-100 Insulin 100 unit/mL (3 mL) subcutaneous pen		50		Unknown	
Dzempic 0.25 mg or 0.5 mg (2 mg/1.5 mL) subcutaneous per njector	n	28		Unknown	
calcium carbonate 500 mg calcium (1,250 mg) tablet		90		Unknown	
smlodipine 5 mg tablet		90		Unknown	
pabapentin 300 mg capsule		30		Unknown	
buprofen 600 mg tablet		14		Unknown	
ficlofenac 1 % topical gel		16		Unknown	
slopidogrei 75 mg tablet		90		Unknown	
naproxen 500 mg tablet		30		Unknown	
oratadine 10 mg tablet		90		Unknown	
oxybutynin chloride 5 mg tablet		90		Unknown	
cholecalcilerol (vitamin D3) 1,250 mcg (50,000 unit) capsule		90		Unknown	
metformin 1,000 mg tablet		30		Unknown	
buprofen 400 mg tablet		14		Unknown	
slopurinol 100 mg tablet		90		Linknown	
slendronate 70 mg tablet		84		Unknown	
Bydureon BCise 2 mg/0.85 mL subcutaneous auto-injector		28		Linknown	
PresStyle Lancets 28 gauge		28		Unknown	
reeStyle Lancets 28 gauge osartan 100 mg-hydrochlorothiazide 25 mg tablet.		90		Unknown	
		90		Unknown	
itorvastatin 40 mg tablet FreeStyle Lite Strips		90		Unknown	
		30			
blood pressure test kit-large cuff				Unknown	
FreeStyle Lite Meter kit		30		Unknown	
Fluzone High-Dese Quad 2022-2023 (PF) 240 mcg/0.7 mL M syringe		1		Unknown	
Pfizer-BioNT COVID19 tris (12y up) Vacc(PF)30 mcg/0.3 mL M susp(gray)		1		Unknown	
sertraline 25 mg tablet		60		Unknown	
orazepam 0.5 mg tablet		30		Unknown	
		60		Unknown	
docusate sodium 100 mg capsule					
docusate sodium 100 mg capsule cholecalciterol (vitamin D3) 50 mog (2,000 unit) capsule		90		Unknown	

Triple Antibiotic 3.5 mg-400 unit-5,000 unit/gram topical ointment	14	Unknown
potassium chloride ER 10 mEg tablet,extended release	30	Unknown
Basaglar KwikPen U-100 Insulin 100 unit/mL (3 mL) subcutaneous	25	Unknown
aspirin 81 mg tablet.delayed release	90	Unknown
dexamethasone 2 mg tablet	5	Unknown
Advair Diskus 100 mcg-50 mcg/dose powder for inhalation	30	Unknown
Situssin-DM 10 mg-100 mg/5 mL oral syrup	14	Unknown
dextromethorphan-guailenesin 10 mg-100 mg/5 mL oral syrup	14	Unknown
azithromycin 250 mg tablet	5	Unknown
Social History		
Basic Social History Queries		
Alcohol intake		
Details of drug Use/Abuse		
Educational achievement		
Employment status		
Exercise		
Health-related behavior		
Marital status		
Nutritional observable		
Others		
Smoking status		
Toxic Exposure Status		
Preventive Screenings		
PHQ-9 Health Assessment All Negative		
Little interest or pleasure in doing things *		
O Not at all O Several days O More than half the d	ava	
Feeling down, depressed, or hopeless *		
O Not at all O Several days O More than half the di	ava	
Trouble failing or staying asleep, or sleeping too much "		
Not at all Several days O More than half the d	1.00	
Feeling tired or having little energy *	470	
O Not at all O Several days. O More than half the d		
Poor appetite or overeating *	uja	
O Not at all O Several days O More than half the d		
Feeling bad about yourself or that you are a failure or have let yo	ourself or your family down *	
O Not at all O Several days O More than half the d	аув	

### History cont.

• Social

### Screenings

- PHQ-9
- Functional Status
- Adv. Care Planning
- Cognitive

al Score *		
you checked off any proble rith other people? *	ms, how difficult have the	ese problems made it for you to do your work, take care of things at home, or get
O Not at all O Severa	I days O More than	half the days
nctional Status Assessment	-	
(IADL/ADL SELECTION): Select IADL or ADL		
O IADL O ADL		
(Instrumental) Activities of I	Daily Living (IADL's):	
Independent of all IADL's	i i i i i i i i i i i i i i i i i i i	
Q Yes Q No		
Shopping for groceries:		
		0
and the second second	O Fully Dependent	O independent
Driving or using public tra	nsportation:	
O Needs Assistance	O Fully Dependent	O Independent
Using the telephone:		
O Needs Assistance	O Fully Dependent	O Independent
Cooking or meal preparat	ion:	
O Needs Assistarios	O Fully Dependent	
Housework:		
0.000	O Fully Dependent	-
	O Fully Dependent	Oudependent
Home repair:		
O Needs Assistance	O Fully Dependent	O (odependent
Laundry:		
O Needs Assistance	O Fully Dependent	O independent
Taking medications:		
O Needa Assistance	O Fully Dependent	
Handling finances:	0.144.444.444	•
	-	
Activities of Daily Living (Al	O Fully Dependent DL's):	O independent
Independent of all ADL's		
O Yes O No		
vanced Care Planning:		
gnitive Assessment: gnitive Functional Assessme	(1994)	

Moving or speaking so slowly that other people could have noticed. Or the opposite being so figely or restless that you have been more around a lot more than usual \*

O Not at all O Several days O More than hall the days Thoughts that you would be better off dead, or of hurting yourself \*

Needs Assistance     Fully Dependent     O Independent     Dressing:
O Needs Assistance O Fully Dependent O Independent
Transferring:
Needs Assistance O Fully Dependent O Independent Tolleting:
O Needs Assistance O Fully Dependent O Independent
Walking:
O Needs Assistance O Fully Dependent O Independent
Discussion documented in the medical record
Legal document present in the medical record
Cognitive Impairment is indicated
O Yes O No
Alert & Oriented
O Yas O No
Memory Deficit
O Yas O No
Immediate Recall
O Yes O No
Falls Risk:
Vision Impsirment
O Yea O No
Mobility Impairment (amputation, paralysis, etc.):
O Yes O No
Household Hazards (stairs, poor lighting, etc.):
O Yes O No
Conditions that affect coordination (i.e., Parkinson's):
O Yes O No
Hearing:
O No impairment O Mild impairment O Profound Impairment
Any assistive devices used (hearing aids, cochear implants, etc.)? ncontinence Assessment: Any urinary incontinence?

### Screenings, cont.

- Falls Risk
- Hearing
- Incontinence
- Nutritional
- Pain
- Phys. Activity
- Safety

Any tecal incontinence?	
O Yes O No	
Nutritional Assessment:	
Eats/Drinks 3 servings of calcium-rich foods daily?	
O Yes O No	
Eats fruits & vegetables every day?	
O Yes O No	
Limits fried food & fast food eaten?	
O Yes O No	
Easily able to get enough healthy food?	
O Yes O No	
Drinks a soda/juice/sports/energy drink most days of the week?	
O Yes O No	
Often ests too much or too little food?	
O Yes O No	
Wiich?	
Concerned about weight?	
O Yes O No	
Has difficulty chewing or swallowing?	
O Yes O No	
Unplanned weight loss in the past 3-6 months?	
O Yes O No	
O < 5% $O > 10%$ $O > 10%$	
Pain Assessment: Acute or chronic pain	
O No pain O Mild O Moderate O Severa O Worst Possible	
Medications used for pain	
Medications have improved pain by	
O 0% O 25% O 50% O 75% O 100%	
Acute or chronic pain	
0 0 1 0 2 0 3 0 4 0 5 0 6 0 7 0 8 0 9 0 10	
Physical Activity Assessment: Physical activities:	
Number of days/week:	
Safety Assessment:	
Do you feel safe where you live?	

O Yes O No				
Have you been hit, or physically hurt by someone th	iis year?			
O Yes O No				
Are tamily and triends worried about your driving?				
O Yes O No				
xual Health Assessment:				
Are you currently sexually active?				
O Yes O No				
Do you think you or your partner could have a sexual	ally transmitted	t infection?		
O Yes O No				
Have you or your partner(s) had sex with other peop	ole in the past	year?		
O Yes O No				
Have you ever been forced or pressured to have se	x?			
O Ves O No				
essment				
roblems* All Activ	Status	Date	HCC	Evaluation*
95.9), Disease of spinal cord, unspecified	Unknown	03/17/2023	Spinal Cord Disorders/Injuries + HCC 72 Recapture	
63), Polyneuropathy in diseases classified elsewhere	Unknown	03/17/2023	Myasthenia Gravis/Myoneural Disorders and Guillain-Barre Syndrome/Inflammatory and Toxic Neuropathy - HCC 75 Recapture	
81.91), Hemiplegia, unspecified affecting right dominant ie	Unknown	03/17/2023	Hemiplegia/Hemiparesis - HCC 103 Recapture	
14.9), Chronic obstructive pulmonary disease, unspecified	Unknown	03/17/2023	Chronic Obstructive Pulmonary Disease - HCC 111 Recapture	
0.32), Chronic diastolic (congestive) heart failure	Unknown	03/17/2023	Congestive Heart Failure - HCC 85 Suspect	
11.20), Opioid dependence, uncomplicated	Unknown	03/17/2023	Drug/Alcohol Dependence - HCC 55 Recepture	
13.1), Major depressive disorder, recurrent, moderate	Unknown	03/17/2023	Major Depressive, Bipolar, and Paranoid Disorders - HCC 59 Recapture	
<ol> <li>Sign 2 diabetes mellitus with moderate nproliferative diabetic retinopathy with macular edema, right e</li> </ol>	Unknown t	03/17/2023	Diabetes with Chronic Complications - HCC 18 Recapture	
(1.51), Type 2 diabetes mellitus with diabetic peripheral giopathy without gangrene	Unknown	03/17/2023	Vascular Disease - HCC 108 Recapture	
3.89), Other cerebral infarction	Unknown	03/17/2023	Ischemic or Unspecified Stroke - HCC 100 Recapture	
1.3553), Type 2 diabetes mellitus with stable proliferative betic re\$nopathy, bilateral	Unknown	03/17/2023	Proliferative Diabetic Retinopathy and Vitreous Hemorrhage - HCC 122 Recepture	
		03/17/2023	Angina Pectoris - HCC	
5.119). Atherosclerotic heart disease of native coronary ery with unspecified angina pectons	Unknown	our triaces	88 Recepture	
5.119), Atherosclerotic heart disease of native coronary ery with unspecified angina pectons 52), Pain, unspecified	Unknown	03/17/2023	88 Recepture	
ery with unspecified angina pectoris 52), Pain, unspecified	1999 - Contractor Contractor Contractor Contractor Contractor Contractor Contractor Contractor Contractor Contra		88 Recapture	
ery with unspecified angina pectoris	Unknown	03/17/2023	88 Recepture	

## Screenings, cont.Sexual Health

# Assessment & Evaluation

• Problems

### Plan

• Quality of Care

20.8). Acute bronchitis due to other specified organisms	Unknown	03/17/2023	
32), Unspecified urinary incontinence	Unknown	03/17/2023	
(79.89), Other specified abnormal findings of blood chemistry	Unknown	03/17/2023	
05.1), Acute cough	Unknown	03/17/2023	
20.822), Contact with and (suspected) exposure to COVID-	Unknown	03/17/2023	
06.9), Acute upper respiratory infection, unspecified	Unknown	03/17/2023	
107.1), COVID-19	Unknown	03/17/2023	
n			
Quality of Care			
Medications have been reviewed			
O Yes O No			
Medication Reconciliation			
O Yes O No O Unable to perform reconcilia	tion		
Documentation of current medications			
O Yes O No			
Transfer of Care - incoming			
O Yes O No			
Transfer of Care - outgoing			
O Yes O No			
Patient Decision Aids / Education Materials Given			
O Yes O No			
Patient Declined to receive clinical summary			
O Yes O No			

### **Form Submissions**

Janet Fina – RA Operations

AWV forms can be accessed by providers in two ways:



1. Cozeva Electronic Form (Opt-In)

Through Cozeva, providers can access an electronic AWV form allowing on-line and real-time access to updated member specific forms.



2. Health Plan Form (Default)

Providers eligible for participation, who do not optin to using Cozeva, will receive member specific AWV forms by SFTP or secure mail (like FedEx). Forms generated through this process are expected to be available in April 2023.



**INSTRUCTIONS:** In order to ensure complete and accurate patient documentation, please fill in all applicable fields in the form below. Once complete, please send the form and corresponding progress note back to BND via eFax (888-531-2152), IPA sFP, or Provider Portal (where applicable). For any questions please reach out to bndaweform@brighthealthcare.com.

#### Annual Wellness Visit (AWV)

INTAKE

Vitals - requ	ired element			
Weight	Height	Temperature	Blood pressure	Pulse
ВМІ	Patient refu	sal of BMI measurement	O2 (if on supplement	ntal oxygen)

HISTORY

 Immunizations
 Administration Date
 Immunization
 Administration Date

 FLU
 10/05/2021
 COVID
 1/27/2022

 PNEUMONIA
 01/11/2022

Lab	Value	Measurement type	Date
Chloride [Moles/Vol]	108.0	mmol/L	2022-12-21
Urea nitrogen [Mass/Vol]	18.0	mg/dL	2022-12-21
Creatinine [Mass/Vol]	0.81	mg/dL	2022-12-21
MCHC Auto (RBC) [Mass/Vol]	32.5	g/dL	2022-12-21
MCV Auto (RBC) [Entitic vol]	92.2	fL	2022-12-21
Lymphocytes Auto (Bld) [#/Vol]	2.00	10^3/uL	2022-12-21
Calcium [Mass/Vol]	10.1	mg/dL	2022-12-21
Basophils Auto (Bld) [#/Vol]	0.04	10^3/uL	2022-12-21
CO2 [Moles/Vol]	29.7	mmol/L	2022-12-21
MCH Auto (RBC) [Entitic mass]	30.0	pg	2022-12-21
RBC Auto (Bld) [#/Vol]	5.03	10^6/uL	2022-12-21
Sodium [Moles/Vol]	144.0	mmol/L	2022-12-21
Potassium [Moles/Vol]	4.5	mmol/L	2022-12-21

Jrea nitrogen/Creatinine [Mass ratio]	22.2	Ratio	2022-12- <mark>2</mark> 1
Tauloj			

Procedure	Start Date	Performer	Notes	
EXCISION LIVER PERQ ENDOSCOPIC APPROACH DX	01/26/2022	GARFIELD MEDICAL CENTER		
RELEASE PERITONEUM PERQ ENDOSCOPIC APPROACH	01/26/2022	GARFIELD MEDICAL CENTER		

Medication	Quantity	Duration	Fill Date (populated by claims)	
Atorvastatin Calcium-10MG TABS	90.00		2022-05-24	Continue Discontinue
Doxazosin Mesylate-4MG TABS	90.000		2023-02-06	Continue
Allopurinol-100MG TABS	90.00		2022-06-22	Continue
Finasteride-5MG TABS	90.00		2022-04-11	Continue
Finasteride-5MG TABS	90.00		2022-10- <mark>1</mark> 2	Continue Discontinue
Atorvastatin Calcium-10MG TABS	90.00		2022-11-16	Continue
Atorvastatin Calcium-10MG TABS	90.000		2023-02-15	Continue
Finasteride-5MG TABS	90.000		2023-01 <mark>-</mark> 09	Continue Discontinue
Atorvastatin Calcium-10MG TABS	90.00		2022-08-22	Continue
Allopurinol-100MG TABS	90.00		2022-12-21	Continue
amLODIPine Besylate-5MG TABS	90.000		2023-01-31	Continue Discontinue
Lisinopril-5MG TABS	90.00		2022-12-21	Continue

Full Medication Reconciliation performed as indicated on attached progress note. Yes No Unable to perform reconciliation.

#### Past Medical - required element

Did you review/update the patient's past medical history during the encounter? 
Yes No

Source	Туре	HCC/HCC Description	Dx Code/Description	Date of Service	Disposition
Claim Data	YOY	96: Specified Heart Arrhythmias	1495 : Sick sinus syndrome	1/4/2023	Assessment/Plan noted in attached progress note Disagree Condition Resolved
Claim Data	YOY	88: Angina Pectoris	I25119 : Atherosclerotic heart disease of native coronary artery with unspecified angina pectoris	1/4/2023	Assessment/Plan noted in attached progress note Disagree Condition Resolved
Claim Data	YOY	108: Vascular Disease	1700 : Atherosclerosis of aorta	1/4/2023	Assessment/Plan noted in attached progress note Disagree Condition Resolved
Claim Data	YOY	85: Congestive Heart Failure	1130 : Hypertensive heart and chronic kidney disease with heart failure and stage 1 through stage 4 chronic kidney disease; or unspecified chronic kidney disease		Assessment/Plan noted in attached progress note Disagree Condition Resolved

#### Family - required element


Did you review/update the patient's family history in the attached progress note?

Social

Did you review/update the patient's social history in the attached progress note? (Examples include Alcohol intake, Details of drug use/abuse, Smoking Status, etc.)

#### CURRENT PROVIDERS/SUPPLIERS

Did you review/update the patient's current provider/suppliers in the attached progress note?  $\square$  Yes  $\square$  No



#### CURRENT BEHAVIORAL RISKS

Opioid Prescription Review - when applicable	
OUD is a complex issue that can occur at any time in one's life and presents differently for e you suspect that your patient may be at risk of struggling with OUD, use the Prescription Op Index (POMI). "Iwo "yes" answers indicate a positive screen and a possible diagnosis of OUD.	veryone. If ioid Misuse
Do you ever use more of your medication, that is, take a higher dose, than is prescribed for you?	🗆 Yes 🗌 No
Do you ever use your medication more often, that is, shorten the time between doses, than is prescribed for you?	🗆 Yes 🗌 No
Do you ever need early refills for your pain medication?	🗆 Yes 🗆 No
Do you ever feel high or get a buzz after using your pain medication?	🗆 Yes 🗌 No
Do you ever take your pain medication because you are upset, using the medication to relieve or cope with problems other than pain?	🗆 Yes 🗌 No
Have you ever gone to multiple physicians, including emergency room doctors, seeking more of your pain medication?	🗆 Yes 🗌 No

Potential substance use disorders (SUDs) Screening - when applicable			
How often do you use Tobacco?	Never 1-2 times a week 3 or more times a week		
How often do you have an alcoholic drink?	□ Never □ 1-2 times a week □ 3 or more times a week		
How often do you use illegal drugs?	□ Never □ 1-2 times a week □ 3 or more times a week		
How often do you use prescription medications recreationally, including using more than prescribed?	□ Never □ 1-2 times a week □ 3 or more times a week		

#### **Health Status**

In general, how would you rate your health? 
\_ Excellent 
\_ Very Good 
\_ Good 
\_ Fair 
Poor
How often do you forget to take your medicine? 
\_ Almost daily 
\_ 2-4 times a week 
\_ 1 time a week 
\_ rarely/never

Do you have difficulty managing your medications? 
Not able to do this activity unassisted

#### FUNCTIONAL STATUS ASSESSMENT

Independent of all ADL's				
Feeding:	Independent Need	s Assistance 🛛 🗆 Fully De	ependent	
Bathing:	Independent Need	s Assistance 🛛 Fully De	ependent	
Dressing:	Independent Need	s Assistance 🛛 🗌 Fully De	ependent	
Transferring:	🗆 Independent 🔲 Need	s Assistance 👘 🗌 Fully De	ependent	
Toileting:	Independent Need	s Assistance 🛛 🗇 Fully De	ependent	
Walking:	□ Independent □ Need	s Assistance 🛛 🗆 Fully De	ependent	

Advanced Care Planning		
Discussion documented in the n	nedical record.	Legal document present in the medical record.
Cognitive Assessment		
Cognitive Assessment performed as noted in the progress note.	🗆 Yes 📋 No	Overall impairment noted:  Yes No (i.e., Mini-Cog)
Fall Risk Assessment		
Vision Impairment:		Yes No
Mobility Impairment (amputation,	paralysis, etc.);	□ Yes □ No
Household hazards (stairs, poor lig		
Conditions that affect coordination	and formers a service	in Region Charles
Recommended anti-slippery socks		□ Yes □ No
Hearing Assessment		
	Yes 🗆 No	Any fecal incontinence?  Yes  No
Any urinary incontinence?	Yes No	
Any urinary incontinence?	Yes No	Any fecal incontinence?  Yes No Concerned about weight? Yes No Unplanned weight loss in the past 3-6 months? Yes
Nutritional Assessment Eats fruit & vegetables every day? Has difficulty chewing or swallowin	Yes No	Any fecal incontinence?  Yes No Concerned about weight? Yes No Unplanned weight loss in the past 3-6 months? Yes
Any urinary incontinence?	Yes No Yes No Yes No Pain Scale: Possible	Any fecal incontinence? Yes No Concerned about weight? Yes No Unplanned weight loss in the past 3-6 months? Yes No If 'Yes', <pre>&lt;5%</pre> 5-10% >10% No pain  Mild  Moderate <pre>Severe </pre> Worst
Any urinary incontinence?	Yes No Yes No Yes No Pain Scale: Possible	Any fecal incontinence? Yes No Concerned about weight? Yes No Unplanned weight loss in the past 3-6 months? Yes No If 'Yes', <pre>&lt;5%</pre> 5-10% >10% No pain  Mild  Moderate <pre>Severe </pre> Worst
Any urinary incontinence?	Yes No Yes No Yes No Yes No Pain Scale: Possible 25% 50%	Any fecal incontinence? Yes No Concerned about weight? Yes No Unplanned weight loss in the past 3-6 months? Yes No If 'Yes', <pre>&lt;5%</pre> 5-10% >10% No pain  Mild  Moderate <pre>Severe </pre> Worst
Any urinary incontinence?	Yes No Yes No Yes No Yes No Pain Scale: Possible 25% 50%	Any fecal incontinence? Yes No Concerned about weight? Yes No Unplanned weight loss in the past 3-6 months? Yes No If 'Yes', <5% 5-10% >10% No pain Mild Moderate Severe Worst One 75% 100%
Any urinary incontinence?	Yes No Yes No Yes No Yes No Pain Scale: Possible 25% 50%	Any fecal incontinence? Yes No Concerned about weight? Yes No Unplanned weight loss in the past 3-6 months? Yes No If 'Yes', <5% 5-10% >10% No pain Mild Moderate Severe Worst One 75% 100%
Any urinary incontinence?	Yes No Yes No Yes No Pain Scale: Possible 25% 50% I activity? (exercise)	Any fecal incontinence? Yes No Concerned about weight? Yes No Unplanned weight loss in the past 3-6 months? Yes No If 'Yes',

	PREVENTIV	E SCREENING	
PHQ-2			
Little interest or pleasur every day	e in doing things: 🗆 Not at	all 🗆 Several Days 🗆 More than	n half the days 🗆 Nearl
Feeling down, depressed every day	d, or hopeless: 🗆 Not at all	Several Days      More than ha	alf the days 🗆 Nearly
If PHQ-2 is positive, con treatment plan, if applic	plete PHQ-9. Document te able.	st and findings in progress note	as well as associated
5	TARS/QUALITY/OTHER	PREVENTIVE SCREENING	
STARS/Quality measu	res - required element		
Exclusion	Frailty & Advanced Illne	55	
Preventive Screening	s & Vaccinations		Dates of Service
Breast Cancer Screening	🗆 Mammogram	🗆 Positive 🗆 Negative	
Exclusions	Bilateral Mastectomy		
	Unilateral Mastectomy		
Colon Cancer Screening (Select Test Type)	Colonoscopy Sigmoidoscopy CT - Colonography Cologuard (Fit-DNA) Fit Kit/FOBT	Positive Negative	
Exclusions	Colon Cancer	Total Colectomy	
Test	Enter Results		Dates of Service
HbA1c	Result:		
Retinal Exam	Not completed	Completed	
	2000 202	Positive Retinopathy Negative Retinopathy	
		Performed by: Optometrist Ophthalmologist	

NOTE: USPSTF recommends against PSA-based screening for men aged 70 years or older.1

Screening	Completed	Result	Date Done	Provider/Facility
	🗆 Yes 🗆 No			
	🗆 Yes 🖂 No			

#### ASSESSMENT/PLAN

Assessment and Plan documented in attached progress note 
Yes 
No
All health conditions should include a diagnosis, status, and treatment plan.

I hereby acknowledge that, to the best of my knowledge, all data on this form is accurate and will become part of the patient's medical record.

Provider Signature: \_\_\_\_

\_\_ Credential: \_\_\_\_\_ Date: \_\_\_\_

Print Name:

Janet Fina – RA Operations

9

## Form Submissions

• Completed AWV Forms and accompanying progress notes for 2023 dates of service must be submitted no later than March 1, 2024, to be eligible for payment.

### **Form Requirements**

Elise Depew – RA Education

 $\bigcirc$ 

All Risk Adjustment & Quality Gaps must be addressed.



If a suspected condition is not present, that condition should be noted as "disconfirmed" on the form.



Referrals for tests to address a Quality gap, such as mammograms, should be noted in the progress note and would be considered "addressed".



All AWV forms must be signed by a clinician.



### **Form Requirements**

Elise Depew – RA Education

On a very limited basis, BND/CHP may allow providers to submit their own AWV form and an accompanying progress note.

Please contact your Provider Service Representative if you would like your form to be reviewed/approved for this program.

If you used your own form in the past, it will need to be reviewed/approved for this year's program.



### **Form Requirements**

### Elise Depew – RA Education



All AWV forms must be submitted with a copy of a progress note.

• Required fields in an AWV are noted in the "AWV Reference Guide"



Providers are also expected to submit an electronic encounter for the visit using one of the following HCPCS codes: G0438, G0439, G0468.

#### Annual Wellness Visit (AWV) Reference Guide

AWV Elements	lents	
Review and update Health Risk Assessment	Patient self-reported information Demographic data Health status self-assessment - Psychosocial risks Behavioral risks Activities of daily living (ADLs)	Best Practice
Update patient's medical and family history	Update and document:     Medical events of parents, siblings, children     Past medical and surgical history     Use of, or exposure to, medications and supplements- med list     review / reconcile present	Required
Update current providers and suppliers list	Include current patient providers and suppliers that regularly provide medical care including any behavior health providers	Required
Measure	Weight     Blood pressure     Other routine measurements deemed appropriate per medical history	Required
Detect any cognitive impairment patient may have	<ul> <li>Access cognitive function by direct observation or family / caregivers.</li> <li>Brief cognitive test -</li> <li>Health disparities or chronic conditions that contribute to increased cognitive impairment risk</li> </ul>	Best Practice
Update patient's written screening schedule	Base written screening schedule on the: United States Preventive Services Task Force and Advisory Committee on Immunization Practices (ACIP) recommendations Patient's HRA, health status and screening history, and age- appropriate preventive services we cover	Required
Update patient's list of risk factors and conditions where you recommend interventions or report current treatment	<ul> <li>Include:</li> <li>Mental health conditions, including depression, substance use disorder(s), and cognitive impairment</li> <li>Risk factors or identified conditions</li> <li>Treatment options and associated risks and benefits</li> </ul>	Best Practice





# **Payment Details**

### **Incentive Payments**

Claire Carey – RA Operations

Payments will be made quarterly, within about 45 days of the quarter end. For example, Q2 2023 payments for AWV forms received by June 30, 2023, will be paid in mid-August.



AWV forms that are properly completed and have an accompanying progress note for the date of service for the visit will be eligible for payment.

Incentive Rewards will be as follows:

Access to AWV form and AWV form submission	Base Rate	Bonus if submitted by 8/1/23	Bonus for SNP members	Potential Total
Using Cozeva	\$175	\$25	\$25	\$225
Non-Cozeva	\$125	\$25	\$25	\$175



Privileged & Confidential | © 2021



# **Next Steps**

### **Next Steps**

Purvi Shah – RA Operations



Decide which option you want to use to participate in the AWE program.



If you're interested in learning more about Cozeva, or moving forward with Cozeva, please contact your Provider Service Representative and let them know.



If you do not want to use Cozeva, and this is your first year participating in the program, please contact your Provider Service Representative to let them know how you would like to receive the PDF (or printed) AWV forms.



If you participated in the AWE program last year (BND providers only), the forms will be distributed the same way as last year.

For any additional questions, please contact your Provider Service Representative.

BND: provider\_services@ universalcare.com

CHP: providerupdate@ centralhealthplan.com

Bright HealthCare

### **Advantages of Using Cozeva**

Purvi Shah – RA Operations



You will be able to track your incentives earned in the Cozeva application.



Data in Cozeva is updated weekly to note newly identified gaps as well as gaps that have been closed.



Incentive program pays out higher amounts per form, for those providers using Cozeva.



### **Upcoming Cozeva Training**

Purvi Shah – RA Operations





**AWV Form Process & Workflow** 

**Supplemental Data** 



Quality & Risk Review



4/12/2023 @ 11 am PST

Join via link: https://cozeva.zoom.us/j/82756110828

Cozeva training recordings will be posted to Healthcare Provider Home | Brand New Day HMO (bndhmo.com) for on demand access!





# **Questions?**

# Thank you!



### Visit our HCC Training page for more resources!

Healthcare Provider Home | Brand New Day HMO (bndhmo.com)